menu
    • menu

    Company profile for Radiopharm Theranostics

    NEW Drugs in Dev: 12
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Radiopharm Theranostics has the ambition to become a recognised leader in the development of radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs.Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Radiopharm TheranosticsAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    Suite 1, Level 3, 62 Lygon Street, Carlton, Victoria 3053
    Telephone
    Telephone
    +61 3 9824 5254
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.radiopharmtheranostics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Radiopharm Theranostics Reports Business Update
    Radiopharm Theranostics Reports Business Update

    23 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/23/3279721/0/en/radiopharm-theranostics-reports-business-update.html

    GLOBENEWSWIRE
    23 Apr 2026
    Share Share
    Radiopharm Completes RAD-101 Brain Trial Enrollment
    Radiopharm Completes RAD-101 Brain Trial Enrollment

    16 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7182260

    FIRSTWORD PHARMA
    16 Apr 2026
    Share Share
    Radiopharm's 177Lu-RAD202 Trial Progresses to Cohort 3
    Radiopharm's 177Lu-RAD202 Trial Progresses to Cohort 3

    08 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/08/3269961/0/en/Radiopharm-Theranostics-Advances-to-Cohort-3-in-177Lu-RAD202-Phase-1-Dose-Escalating-Clinical-Trial.html

    GLOBENEWSWIRE
    08 Apr 2026
    Share Share
    Radiopharm Theranostics, Siemens Sign RAD101 Agreement
    Radiopharm Theranostics, Siemens Sign RAD101 Agreement

    07 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/07/3268954/0/en/Radiopharm-Theranostics-and-Siemens-Healthineers-Sign-Clinical-Supply-Agreement-for-RAD101-in-the-U-S.html

    GLOBENEWSWIRE
    07 Apr 2026
    Share Share
    Radiopharm Theranostics Initiates RAD 402 Phase 1 Trial
    Radiopharm Theranostics Initiates RAD 402 Phase 1 Trial

    27 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/27/3263666/0/en/Radiopharm-Theranostics-Doses-First-Patient-in-Phase-1-Clinical-Study-of-RAD-402-in-Advanced-Prostate-Cancer.html

    GLOBENEWSWIRE
    27 Mar 2026
    Share Share
    Radiopharm Meets Primary Endpoint in 90% of RAD-101 Patients
    Radiopharm Meets Primary Endpoint in 90% of RAD-101 Patients

    24 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/24/3261071/0/en/Radiopharm-Theranostics-Achieves-Primary-Endpoint-In-90-of-Patients-At-Second-Interim-Analysis-of-RAD-101-Phase-2b-Imaging-Trial-in-Brain-Metastases.html

    GLOBENEWSWIRE
    24 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search